Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

Cancer Treat RevJun 25, 2026 (epub)

Andrea Pretta, Riccardo Giampieri, Andrea Bottelli et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of RAS and BRAF mutational status on outcomes in patients with MSI-H/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs). Among 2564 patients from nine studies, RAS-mutated disease was linked to longer progression-free survival (PFS) (HR 0.81), while BRAF mutations were associated with shorter PFS (HR 1.37) and worse overall survival (OS) (HR 1.74).

Key findings

RAS-mutated disease was associated with longer PFS (HR 0.81, 95% CI 0.66-0.99).
BRAF-mutated tumours showed shorter PFS (HR 1.37, 95% CI 1.11-1.69).
Overall survival was significantly worse in BRAF-mutated disease (HR 1.74, 95% CI 1.17-2.59).
Response rates may increase with dual checkpoint blockade in BRAF-mutated and wild-type subgroups.

Why it matters

Understanding the distinct outcomes based on RAS and BRAF status in MSI-H/dMMR mCRC can guide clinicians in personalizing immunotherapy approaches, potentially improving patient management and outcomes.

Source

PubMed · PMID 42497817

Published in Cancer Treat Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegram LinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary

Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary

Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

Your specialties
Your filters and thresholds
Clinical Research + Case Reports, tuned separately
Automatic weekly delivery
Audio and text

Create my personalized digest See plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.